KIT and small cell lung carcinoma: However, clinical trials have reported that treatment with imatinib does not result in any clinical benefits in patients with SCLC [18, 19, 20, 21], which suggests that the SCF/c‐Kit pathway is not the major pathway mediating the pathogenesis of SCLC.